The Billion-Dollar Surgical Complication Nobody Talks About: Surgical Nerve Injury
- Mar 24
- 5 min read
Every surgeon is trained to respect nerves.
They are delicate, unforgiving structures. Difficult to see, easy to damage, and slow to heal. Yet despite that awareness, nerve injury remains one of the most common and consequential complications in modern surgery.
What makes this problem uniquely challenging is not just its severity, but its invisibility. Nerve injury rarely presents as a dramatic intraoperative event. More often, it reveals itself later - through dysfunction, pain, or paralysis that patients carry long after the procedure is over. Nerves don't heal easily, and injuries to these critical structures can lead to life long disability.
And when you look closely at the data, one thing becomes clear:
This problem is far larger than most people realize.
A Problem That Spans Every Surgical Specialty
Nerve injury is not confined to a single type of procedure. It is pervasive across nearly every field of surgery, from oncology to orthopedics to cardiovascular care. Here are some common procedure examples:
INDICATION | VOLUME (GLOBAL PATIENTS/YEAR) | RISK OF NERVE DAMAGE | CITATION |
Prostatectomy | 525,000 | 60-85% | |
Colorectal Cancer Resection | 1,800,000 | 30-70% | |
Thyroidectomy | 3,800,000 | 14-26% | |
Discectomy | 6,900,000 | 2-8% | |
Hip & Shoulder Arthroplasty | 11,500,000 | 2-25% | |
Inguinal Hernia Repair | 15,000,000 | 5-50% |
Even in procedures considered “routine,” nerve injury quietly accumulates.
Across all specialties, 25 million nerve injuries occur worldwide, leaving over 100 million patients at risk every year. Here is the general breakdown by speciality:
When Nerve Injury Doesn’t Look Like Nerve Injury
One of the most important - and overlooked - insights from the data is that nerve injury is often not labeled as such.
Take colorectal surgery. Following low anterior resection, up to 44% of patients develop major low anterior resection syndrome (LARS), characterized by bowel dysfunction, urgency, and incontinence. While this is typically discussed as a functional gastrointestinal outcome, the underlying mechanism frequently involves autonomic nerve injury during pelvic dissection.
Similarly, in urologic surgery, erectile dysfunction following cystectomy or prostatectomy is reported in over 70% of patients in some series. Yet again, this is rarely framed explicitly as nerve injury - even though it directly reflects damage to pelvic autonomic nerves.
This pattern repeats across specialties:
Bowel dysfunction becomes “LARS”
Sexual dysfunction becomes a “quality of life outcome”
Chronic pain becomes a “postoperative syndrome”
The underlying cause, nerve injury, is often hidden in plain sight and patients are left dealing with chronic side effects to their surgery.
Financial Cost of Nerve Injuries
Nerve injuries are not only devastating for patients, but they are also expensive for the patient, payer, and hospital.
Recent U.S. data shows the average total cost of treating a peripheral nerve injury is approximately $31,000 per patient, and can exceed $60,000 for cases requiring inpatient care and rehabilitation.
These costs include:
Direct medical costs such as additional surgeries, hospital stays, medications, and rehabilitation
Imaging and follow-up care such as rehabilitation and physical therapy
Indirect costs include lost productivity, disability payments, and long-term care
long-term concerns such as pain management, lost productivity, and disability
In many cases, these costs persist for years or decades. When observed across the large number of nerve injuries each year, nerve damage represents a multi-billion-dollar burden on healthcare systems and hospitals. Importantly, because nerve injury is inconsistently labeled, its economic burden is also underestimated.
For example, a study published in The Journal of Bone & Joint Surgery found that patients with major complications like nerve injuries after orthopedic surgery had hospital costs nearly double those without nerve damage. This highlights the urgent need for effective prevention strategies.
Why Nerve Injury Is Systematically Underreported
The underreporting of nerve injury is not accidental. It is structural.
First, many nerve injuries are not immediately apparent. Unlike bleeding or organ damage, nerve dysfunction often emerges days, weeks, or even months after surgery. By the time symptoms develop, attribution to the original procedure may be unclear or contested - and chance of effective repair is dramatically reduced.
Second, surgical reporting systems are not designed to capture functional outcomes with high fidelity. Registries prioritize mortality, infection, and major complications - not subtle or delayed neurologic deficits. As a result, many nerve injuries fall outside standardized reporting frameworks.
Third, there is a fundamental issue of attribution. In complex surgeries - particularly oncologic procedures - functional deficits are often attributed to disease severity and extent of resection required rather than surgical technique. This creates a gray zone where nerve injury is expected, but not explicitly documented.
Finally, both patients and providers contribute to underreporting. Patients may normalize symptoms like numbness or sexual dysfunction as part of recovery, while clinicians may avoid formally documenting complications that are difficult to quantify or that carry medicolegal implications.
The result is a consistent pattern:
What gets reported is only a fraction of what actually occurs.
How Trace Biosciences Is Stepping In To Prevent Nerve Injury
Currently, surgeons often rely on neuroanatomical knowledge and conventional white light visual inspection to locate and identify nerve tissue intraoperatively. Unfortunately, in many surgeries, because nerves are small, hidden, or difficult to distinguish from surrounding tissue and blood, this can lead to an increased risk of accidental nerve damage and outcomes are significantly associated with a surgeon's experience level.
Up until now, this has been unavoidable.
This is where Trace Biosciences comes in.
Trace Biosciences has developed first-in-kind, small molecule, targeted clinically translatable NIR nerve-specific fluorophores that label nerve tissue with high affinity.
Our novel fluorophores have demonstrated :
High nerve signal to allow for clear visualization of nerves
Nerve binding & specificity against all background tissue
Near-infrared (NIR) fluorescence
Compatibility with clinically available imaging systems
Trace Biosciences' agents have been specifically designed to seamlessly integrate into existing fluorescence-guided surgery (FGS) imaging systems by operating at near-infrared (NIR) wavelengths (650-900 nm) to enable fluorescence imaging of structures buried in the native tissue environment, reducing overall complications.
What Is Fluorescence-Guided Surgery & What Are The Benefits?
Fluorescence-guided surgery (FGS) is a form of surgical guidance that seeks to improve the safety and efficacy of surgery through machine-assisted visual identification.
Its benefits include:
Real-time, non-contact visual differentiation of fluorophore-labeled tissue
Identification of unseen structures without altering the appearance of the surgical field
By integrating these methods, Trace Biosciences supports surgeons in making informed decisions that protect nerves and improve patient outcomes. Instead of relying solely on anatomy, surgeons can now see functional structures directly. This reduces the likelihood of injury, lowers patient risk, and decreases associated costs.
This shift is subtle but profound. It moves surgery from estimation to precision - from avoiding nerves based on expectation, to actively identifying and preserving them.
Potential Benefits for Patients and Providers
Fewer complications and faster recovery times.
Reduced need for follow-up surgeries and treatments.
Improved patient satisfaction and quality of life.
Lower overall healthcare expenses related to nerve injuries.
If nerve injury is fundamentally a visibility problem, then improving visualization is not just an incremental advance - it is a paradigm shift. Trace Biosciences is excited to begin clinical testing to collect evidence supporting all of these valuable benefits and beyond.
The Future Of Surgery Is Visualized Fluorescence
Nerve injury is one of the most pervasive, costly, and underrecognized challenges in surgery today. It affects millions of patients each year, often with lifelong consequences. Yet it remains underreported, inconsistently defined, and frequently hidden behind broader clinical diagnoses. Understanding the scale of this problem is the first step toward better prevention.
Trace Biosciences provides practical, technology-driven solutions that empower surgical teams to protect critical nerves through fluorescence-guided surgery. Our agents offer a clear path to reducing nerve injury rates, improving patient outcomes, and lowering costs.
Preventing nerve injury not only saves money, it preserves mobility, sensation, and quality of life.
And these are problems worth solving.
Comments